Soligenix, a development-stage biopharmaceutical company, has formed a medical advisory board to provide medical/clinical strategic guidance to the company as it advances the development of SGX942 for the treatment of oral mucositis, a common complication of cancer treatments.
The board will provide feedback, input, and guidance on clinical strategies and their implementation, as well as on other critical issues, such as health economics and reimbursement, to assist Soligenix in meeting the needs of the oral mucositis patient population.
The board members are Stephen Sonis, DMD, DMSc, a clinical professor of oral medicine at Harvard School of Dental Medicine; Dorothy M.K. Keefe, MD, a professor of cancer medicine at the University of Adelaide and a senior medical oncologist at Royal Adelaide Hospital Cancer Centre; and Mark M. Schubert, DDS, MSD, a professor in the department of oral medicine at the University of Washington School of Dentistry and the director of oral medicine with the Seattle Cancer Care Alliance.
"Oral mucositis is a significant unmet medical need which ultimately impacts the tolerability of radiation and chemotherapy and therefore the survivability of cancer," Dr. Sonis stated in a press release. "The lack of an effective treatment has frustrated healthcare providers and caused misery for innumerable patients. I'm delighted to be helping to develop SGX942 as I believe it holds significant promise as a mucositis intervention. As an innate defense regulator, SGX942 directly targets a fundamental biological mechanism which leads to mucosal injury caused by radiation and chemotherapy."
